Liquidia Corporation (NASDAQ: LQDA) reported significant progress in Q2 2025, highlighted by the successful launch of YUTREPIA™ (treprostinil) inhalation powder. Following FDA approval in May 2025, the drug achieved over 900 unique patient prescriptions and 550 patient starts within 11 weeks for treating PAH and PH-ILD.
The company's interim ASCENT trial data showed promising results, with patients demonstrating a median improvement in six-minute walk distance of 31.5 meters at Week 16. Financially, Liquidia reported $173.4M in cash, generated $6.5M in product revenue, and recorded a net loss of $41.6M ($0.49 per share) for Q2 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.